Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 91 to 100 of 2440 total matches.
Glucagon Nasal Powder (Baqsimi) for Severe Hypoglycemia
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
see' mee
SEVERE HYPOGLYCEMIA – Hypoglycemia is
classified as level 1 (blood glucose ≥54 and ...
The FDA has approved glucagon nasal powder
(Baqsimi – Lilly) for treatment of severe hypoglycemia
in patients ≥4 years old with diabetes. Baqsimi is the
first noninjectable glucagon formulation to become
available in the US. Injectable glucagon emergency kits
(GlucaGen Hypokit, and generic) have been available
for years, but they require reconstitution of the
lyophilized powder by the caregiver immediately before
injection. An injectable glucagon formulation that does
not require reconstitution was recently approved by the
FDA (Gvoke) and is expected to become available...
Linagliptin/Metformin (Jentadueto) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 14, 2012 (Issue 1390)
require treatment with multiple drugs.1 Linagliptin is
a dipeptidyl peptidase-4 (DDP-4) inhibitor like ...
Linagliptin (Tradjenta) and metformin (Glucophage,
and others) are now available as a fixed-dose combination
(Jentadueto – Boehringer Ingelheim/Lilly) for
oral treatment of type 2 diabetes in adults. Metformin
is generally the preferred first-line agent for treatment
of type 2 diabetes, but most patients eventually
require treatment with multiple drugs. Linagliptin is
a dipeptidyl peptidase-4 (DDP-4) inhibitor like
sitagliptin (Januvia) and saxagliptin (Onglyza). Both
sitagliptin and saxagliptin are also available in fixed-dose
combinations with...
Simeprevir (Olysio) for Chronic Hepatitis C
The Medical Letter on Drugs and Therapeutics • Jan 06, 2014 (Issue 1433)
COPYRIGHT LAWS 1
The FDA has recently approved 2 new drugs for treatment
of chronic hepatitis C virus (HCV ...
The FDA has recently approved 2 new drugs for treatment of chronic hepatitis C virus (HCV) infection. Simeprevir (Olysio – Janssen) is the third oral protease inhibitor to be approved for use in combination with peginterferon and ribavirin for treatment of chronic HCV genotype 1 infection in adults with compensated liver disease. Telaprevir (Incivek) and boceprevir (Victrelis) were approved in 2011 for the same indication. Sofosbuvir (Sovaldi – Gilead), a nucleotide analog polymerase inhibitor that has been approved for use with and without interferon for treatment of multiple HCV...
Cetirizine Ophthalmic Solution (Zerviate) for Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020 (Issue 1599)
compresses, and avoidance of eye rubbing and contact
lens wearing during symptomatic periods.1
Many ...
A 0.24% ophthalmic solution of the second-generation
H1-antihistamine cetirizine (Zerviate – Eyevance) is now
available by prescription for treatment of ocular itching
associated with allergic conjunctivitis in patients ≥2
years old. Oral cetirizine (Zyrtec, and others), which is
used for treatment of allergic conjunctivitis and rhinitis,
has been available over the counter (OTC) for years.
Tapinarof Cream (Vtama) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
' uh
The FDA has approved Vtama (Dermavant), a 1%
cream formulation of the aryl hydrocarbon receptor ...
The FDA has approved Vtama (Dermavant), a 1%
cream formulation of the aryl hydrocarbon receptor
(AhR) agonist tapinarof, for treatment of adults with
plaque psoriasis. It is the first AhR agonist to be
approved by the FDA.
A Three-Antigen Hepatitis B Vaccine (PreHevbrio)
The Medical Letter on Drugs and Therapeutics • May 16, 2022 (Issue 1650)
hepatitis B vaccination rate among
adults was 30%.1
NEW RECOMMENDATIONS — The Advisory Committee ...
The FDA has licensed PreHevbrio (VBI Vaccines), a
recombinant, 3-antigen, 3-dose hepatitis B vaccine,
for the prevention of infection caused by all known
subtypes of hepatitis B virus (HBV) in adults. It has
been available in Israel since 2000.
Initial Therapy of Hypertension
The Medical Letter on Drugs and Therapeutics • Jul 05, 2004 (Issue 1186)
risk of stroke (6.3% vs. 5.6%), heart failure (8.7% vs. 7.7%), angina (13.6% vs. 12.1%) and
combined ...
The importance of adequate control of hypertension in preventing organ damage and death is well established, but the choice of drugs is still controversial. Three recent drug trials, one supporting initial therapy with a diuretic, the second favoring an angiotensin converting enzyme (ACE) inhibitor, and the third showing equivalence between a calcium-channel blocker and an angiotensin-receptor blocker (ARB) have intensified the debate.
Comparison Table: Some Nasal Sprays for Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • Apr 19, 2021 (Issue 1622)
Usual Dosage Comments Class Comments Cost1
H1-Antihistamines
Azelastine 0.1%–
generic
Azelastine ...
View the Comparison Table: Some Nasal Sprays for Allergic Rhinitis
In Brief: Shingrix for Immunocompromised Adults
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021 (Issue 1631)
or immunosuppression.
Shingrix has been licensed for herpes
zoster prevention in adults ≥50 years old since 2017.1 ...
The FDA has licensed the adjuvanted, recombinant
varicella zoster virus (VZV) vaccine Shingrix (GSK) for
prevention of herpes zoster (shingles) in adults of any
age who are or will be at elevated risk because of disease-
or therapy-induced immunodeficiency or immunosuppression.
Shingrix has been licensed for herpes
zoster prevention in adults ≥50 years old since 2017.1
It is the only VZV vaccine currently available in the US;
Zostavax, a live-attenuated VZV vaccine, was withdrawn
from the market in 2020.
Topical Drugs For Vaginal Candidiasis
The Medical Letter on Drugs and Therapeutics • Aug 23, 1991 (Issue 851)
− Syntex 2% cream
Clotrimazole
7 tabs − 15.77Gyne-Lotrimin − Schering (OTC) 100-mg vaginal tablet 1 ...
Many drugs, mostly imidazole derivatives, are marketed in the USA for topical treatment of vulvovaginal candidiasis, and a few are now available without a prescription.